Has Devjit Tripathy received payments from drug or device companies?

Yes. Drug and device makers reported $783 in general payments to Devjit Tripathy across 10 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Devjit Tripathy did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Devjit Tripathy come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Devjit Tripathy

Endocrinology, Diabetes & Metabolism · San Antonio, TXNPI 1841207172

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Medtronic at 37.0% of the total. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in TX, where the typical reported total is $2,974.

$783in general payments, 2019–2025

Across 10 payments — averaging $78.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$290
Sanofi-aventis U.S. LLC$210
Bayer$110
Novo Nordisk$105
Novartis$69

$1,515,454in research payments, 2019–2025

Across 519 payments — averaging $2919.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$670K
Novo Nordisk AS$476K
Sanofi US Services Inc.$265K
AbbVie$89K
Pfizer$9K
GSK$3K
plus $2K from 1 others

What the payments were for

Food & beverage$783100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	3	$290
Sanofi-aventis U.S. LLC	2	$210
Bayer	3	$110
Novo Nordisk	1	$105
Novartis	1	$69

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$783 in reported general payments places this provider in the 25th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Other endocrinology, diabetes & metabolism in San Antonio

Ralph DefronzoSan Antonio$880K
Firas AkhrassSan Antonio$801K
Carolina Solis-HerreraSan Antonio$600K
Jeannie BaqueroSan Antonio$573K
Kathleen HandsSan Antonio$223K
Shahid AzizSan Antonio$173K
William TrigosoSan Antonio$170K
Lance SloanLufkin$1.7M
Pablo MoraDallas$1.3M
Robert HoodBeaumont$1.3M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →